Date: 2011-05-12
Type of information: Fundraising
Company: Midatech (UK)
Investors:
Amount: £6.3 Million (€7.6 million)
Funding type: private investment round
Planned used: This financing will be used to strengthen and diversify Midatech’s product development portfolio, especially in oncology. It will be used to support clinical development of chemotherapeutic gold nanoparticles designed to target ovarian, lung and breast carcinoma and to support development of therapeutic cancer vaccines in SynTara, a joint venture with Immunotope Inc. The funding will also be used to expand the capacity of Midatech’s resources to accommodate its expanding development portfolio.
Others: Midatech Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, has raised £6.3 million through a private investment round. In November 2011, Midatech received regulatory approval for a first-in-human study of MidaForm™ insulin delivered transbuccally. Phase I results are expected in Q1 2012.
Therapeutic area: Cancer - Oncology
